June 17, 2024
Loading...
You are here:  Home  >  Health Care & Life Science  >  Current Article

Biosimilar competition hurts Amgen’s top line

IN THIS ARTICLE

Thousand Oaks-based Amgen delivered a sound earnings beat in the first quarter of 2023, the company announced after the markets closed on April 27. Amgen, one of the largest biotechnology companies in the world, generated net income worth $2.8 billion in the first quarter or $5.28 earnings per share. This nearly doubled last year’s first-quarter…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.